Clinical trials exploring IL-12/IL-23 inhibitors’ effects in IBD treatment, alongside the causal relationship between elevated IL18 levels and IBD susceptibility, suggest repositioning existing drugs targeting IL18 signaling for IBD treatment, highlighting the therapeutic potential of targeting the IL18/IL18R1 pathway (61, 65). The gene discussed is IL18; the disease is inflammatory bowel disease.